NewsRoom Articles - Page 138 of 207

MondayAug 23, 2021 10:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Operational, Financial Report

Q1 2021 report notes distinction of becoming first psychedelic company to list on the NYSE American LLC stock exchange Cybin has garnered “a great deal of attention as an emerging leader in the psychedelic therapeutics space,” says CEO Several of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline Cybin (NEO: CYBN) (NYSE American: CYBN) is wrapping up a highly successful first quarter with the release of its Q1 2021 operational and financial report, for the period ended June 30, 2021 (https://ibn.fm/V9xNp). The biotech company, which is focused on progressing psychedelic therapeutics, hit some milestones this quarter,…

FridayAug 20, 2021 11:08 am

Current Bladder Cancer Treatments May Adversely Affect Patients’ Psychosocial Well-Being

A study that was recently published in the “International Journal of Urological Nursing” found that intravesical therapy affected the physical, emotional and social well-being of patients who suffered from non-muscle invasive bladder cancer. The participants of the study underwent intravesical therapy together with either mitomycine (“MMC”) or Bacillus Calmette-Guerin (“BCG”) treatments. The objective of the authors of the study was to evaluate the psychosocial issues these study subjects experienced during therapy and what effects those challenges triggered. In their report, the authors stated that the patients struggled to cope with treatment side effects, adding that this was in addition to…

FridayAug 20, 2021 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) 2021 Growth Strategy Update

So far in 2021, Mind Cure has embarked on an aggressive plan to strengthen its advisory board and file for new provisional patents for its fully synthetic ibogaine In January, the company also announced an amended agreement to grow the size of an earlier-announced bought deal financing This year has also seen the launch of the second stage of manufacturing of Ibogaine for use in psychedelic clinical research Mind Cure also continues to strengthen its proprietary digital therapeutics technology (“DTx”), iSTRYM All of Mind Cure’s decisions thus far are designed to help the company achieve overall growth and fulfill its vision of easing suffering, increasing productivity, and enhancing mental health Mind Cure…

ThursdayAug 19, 2021 11:23 am

Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Adelia Acquisition Making Impact, Reaching Milestones

Cybin subsidiary achieved certain milestones as outlined in acquisition agreement Adelia brought numerous advantages to company Acquisition may advance “Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” says CEO Cybin's (NEO: CYBN) (NYSE American CYBN) most recent acquisition, Adelia Therapeutics Inc., is already reporting success for the company (https://ibn.fm/ZtWL2). Cybin recently announced that the wholly controlled subsidiary had achieved certain milestones for the year as outlined in the acquisition agreement, resulting in Adelia shareholders receiving common shares in Cybin. Cybin closed on the acquisition of Adelia late last year, with the company noting…

ThursdayAug 19, 2021 11:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with Calvert Labs, Gad Consulting Services to Conduct Preclinical Bridging Studies in Preparation for Phase 2b Clinical Trials

Tryp Therapeutics recently announced new agreements with Calvert Labs and Gad Consulting Services, the second in a series of upcoming bridging studies aimed at facilitating the advancement of TRP-8803 into Phase 2b clinical trials Calvert Labs will design and execute the exploratory studies, while Gad Consulting Services will advise on certain aspects of the studies Calvert Labs shall perform TRP-8803 and TRP-8802 are psilocybin-based products being evaluated under Tryp’s PFN program Tryp intends to use TRP-8802 in the Phase 2a clinical trials, while TRP-8803 will be used in Phase 2b clinical trials and beyond The San Diego-based pharmaceutical company, Tryp…

ThursdayAug 19, 2021 10:07 am

Brain Scientific Inc. (BRSF) Addresses Growing Epilepsy Problem With Portable Low-Cost Brain Monitoring Devices

CDC reports epilepsy is growing problem, 3.4 million people afflicted in the US According to report, adult cases rose from 2.3 million to 3 million between 2010 and 2015, pediatric cases increased 450,000 to 470,000 over same period Brain Scientific produces patented devices that can be used to provide instant EEG tests to millions of US hospital patients each year More Americans are suffering from epilepsy than ever before, according to a report by the Center for Disease Control (“CDC”) that states that at least 3.4 million people live with the disorder in the United States (https://ibn.fm/PmF2b). Brain Scientific (OTCQB:…

ThursdayAug 19, 2021 9:30 am

Chronic Pain May Influence How Your Brain Processes Emotions

A study conducted by researchers from NeuRA and the University of New South Wales Sydney has found that individuals with chronic pain have a neurotransmitter imbalance in the area of the brain that is responsible for regulating emotions. The study was published in the “European Journal of Pain.” Estimates show that more than three million individuals in Australia are plagued with chronic pain, which can affect many parts of an individual’s life; more than half of these individuals also experienced depression and anxiety disorders. The researchers hypothesize that the neurotransmitter imbalance could be making it more difficult for these individuals…

WednesdayAug 18, 2021 12:15 pm

Routine Cancer Screening Declines During Pandemic

At the onset of the pandemic, restrictions on moving around were implemented, with social distancing and other measures being taken to avoid virus spread. As people have adjusted to a “new” normal, fewer and fewer individuals have been returning to their physicians for their annual cancer screenings. Cancer screening is basically getting checked for cancer by your physician before you begin displaying any symptoms. Regular screening may find colorectal, cervical and breast cancers in their early stages when treatment will be more effective, in comparison to late-stage diagnoses. Estimates from the Centers for Disease Control and Prevention show that the…

TuesdayAug 17, 2021 11:09 am

Less TV, More Physical Exercise Reduces Sleep Apnea Risks

According to a new study, people who spend less time watching TV and are physically active face a diminished risk of suffering from obstructive sleep apnea. This is the first research to examine sedentary lifestyles as well as physical activity with respect to the risk of developing obstructive sleep apnea. Obstructive sleep apnea is a condition in which an individual stops breathing and then restarts breathing again; this pattern carries on multiple times as the person sleeps. As a result of this intermittent breathing, the person’s blood oxygen concentration drops, they feel very tired, they snore, and their sleep is…

TuesdayAug 17, 2021 9:30 am

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary AI Model Predicts Cancer Outcomes, Leads to New Therapies

AI models of genomic data can predict cancer outcomes, which can then help personalize ovarian cancer treatments Results come from Helomics’ work on the 100,000 Genomes Project in Genomics England’s National Genomic Research Library Model learns patterns in genetic mutations of patients’ tumors, uses that knowledge to predict patient survival In an historic announcement in the space where artificial intelligence and precision medicine intersect, Predictive Oncology (NASDAQ: POAI) has released initial results for its AI-driven models of ovarian cancer (https://ibn.fm/H3As3). According to Predictive Oncology, the initial results demonstrate that AI models of genomic data can predict cancer outcomes which has…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Operational, Financial Report

Current Bladder Cancer Treatments May Adversely Affect Patients’ Psychosocial Well-Being

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) 2021 Growth Strategy Update

Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Adelia Acquisition Making Impact, Reaching Milestones

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with Calvert Labs, Gad Consulting Services to Conduct Preclinical Bridging Studies in Preparation for Phase 2b Clinical Trials

Brain Scientific Inc. (BRSF) Addresses Growing Epilepsy Problem With Portable Low-Cost Brain Monitoring Devices

Chronic Pain May Influence How Your Brain Processes Emotions

Routine Cancer Screening Declines During Pandemic

Less TV, More Physical Exercise Reduces Sleep Apnea Risks

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary AI Model Predicts Cancer Outcomes, Leads to New Therapies

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search